Investment Overview
Leidos, a technology company, is investing $10 million in a collaboration with the University of Pittsburgh to enhance the use of artificial intelligence (AI) for disease detection and management.
Collaboration Goals
This five-year partnership focuses on:
- Developing AI-powered tools for quicker detection of diseases such as heart disease and cancer.
- Reducing diagnostic turnaround times to enable earlier and more effective care management.
- Establishing a research hub at the University of Pittsburgh to advance digital pathology and diagnostics.
Research and Development
The collaboration will involve:
- Joint research projects to explore new imaging methods and advanced scanning technologies for tissue sample analysis.
- Improving techniques for analyzing medical images.
Educational Initiatives
The initiative will also include:
- Educational programs and symposiums.
- Hands-on internships for students to work alongside Leidos employees.
Leadership Statements
Leidos CEO Tom Bell stated, “Our investment is aimed at using the power of artificial intelligence to speed detection, diagnosis, and treatment of diseases affecting millions annually.” He emphasized the importance of developing future healthcare specialists and expanding care for underserved communities, including veterans.
Broader Context
Recently, Leidos has also partnered with Moveworks, an AI assistant, to enhance government worker efficiency in the U.S., UK, and Australia. Additionally, the company announced a new uncrewed undersea vessel, Sea Dart, to support various missions for the U.S. Navy and commercial clients.
Future Prospects
Leidos aims to leverage this collaboration to deploy AI-powered digital pathology solutions across both public and private healthcare sectors, ultimately leading to the commercialization of innovative healthcare technologies.